Short answer
Lexeo Therapeutics, Inc. (LXEO) filed its Q3 2026 10-Q quarterly report on Nov 16, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$38M
- −88.8% YoY · −48.1% QoQ
- EPS (diluted)
- −$0.44
- −131.6% YoY · −46.7% QoQ
Source: XBRL data from the Lexeo Therapeutics, Inc. (LXEO) Q3 2026 10-Q on SEC EDGAR. USD.
Lexeo Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, with no product sales generated
- Net loss $38.3M vs $20.3M YoY, operating loss $40.4M vs $21.6M
- LX2006 R&D $12.7M vs $5.1M, best-performing program by quarterly spending
- Cash, equivalents and Treasury investments $219.1M vs $246.6M at year-end; operating cash outflow $67.3M
- Management expects funding into 2028, with continued losses and significantly higher development expenses ahead
Risk Factors
- Newly added regulatory risk: 2026 legislation codified orphan exclusivity by approved indication and extended pediatric priority vouchers only through September 30, 2029
- Most materially updated FDA risk: agency reorganization, potential shutdowns, layoffs, and resource constraints could delay reviews, approvals, and inspections
- Clinical safety risk: LX2006 preclinical studies observed four hepatocellular carcinomas in wild-type mice 10 months after treatment
- Competitive risk: LX2006 faces Solid Biosciences, Voyager-Neurocrine, Larimar, Design Therapeutics, and PTC Therapeutics programs
- Liquidity risk: $219.1 million in cash, cash equivalents, and U.S. Treasury investments expected to fund operations into 2028
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Lexeo Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.